Overview Natrunix in HLA-B27 Positive Subjects With Axial Spondyloarthritis Status: NOT_YET_RECRUITING Trial end date: 2025-04-30 Target enrollment: Participant gender: Summary Double-blind, placebo-controlled, randomized trial of Natrunix in combination with Standard of Care in patients with Axial SpondyloarthritisPhase: PHASE2 Details Lead Sponsor: XBiotech, Inc.